2022 World Conference on Lung Cancer (ePosters)-EP04.01-015. Lung Cancer after Solid Organ Transplantation

Pdf Summary

Solid organ transplant recipients face a higher risk of developing cancer due to immunosuppression. This study analyzed claims data from over 36,000 German lung cancer patients to compare outcomes in patients with and without a prior solid organ transplant (SOT). Out of the total cohort, 85 patients had undergone SOT before their lung cancer diagnosis. Propensity score matching was used to create a control group of 255 patients without SOT who were comparable in terms of age, sex, metastasis status, regional type of residence, and hospital size.<br /><br />The analysis found that patients with SOT had a higher burden of comorbidity compared to those without SOT. The prevalence of pneumonia was also significantly higher in SOT patients. Additionally, patients with SOT had significantly higher overall costs and inpatient costs over a three-year period.<br /><br />In terms of therapy, the study found that patients with SOT had different treatment patterns. Surgery was the most common therapy for both groups, but SOT patients were less likely to undergo systemic therapy and more likely to receive radiotherapy. A small percentage of SOT patients received no tumor therapy at all.<br /><br />The study also compared survival rates and found that patients with SOT had poorer survival outcomes compared to those without SOT.<br /><br />In conclusion, prior SOT is a significant comorbidity that leads to a higher vulnerability to pneumonia and poorer survival outcomes in lung cancer patients. The increased use of healthcare resources for SOT patients also results in higher expenditures for health insurance companies.

Asset Subtitle

Julia Walter

Meta Tag

Speaker Julia Walter

Topic Global Health, Health Services Research, and Health Economics - Cost Issues

Keywords

solid organ transplant recipients

cancer risk

immunosuppression

German lung cancer patients

outcomes

comorbidity burden

pneumonia prevalence

healthcare costs

treatment patterns

survival outcomes